TAILIEUCHUNG - Chapter 108. Hematopoietic Cell Transplantation (Part 7)

Pneumocystis jiroveci pneumonia, once seen in 5–10% of patients, can be prevented by treating patients with oral trimethoprim-sulfamethoxazole for 1 week pretransplant and resuming the treatment once patients have engrafted. The risk of infection diminishes considerably beyond 3 months after transplant unless chronic Most GVHD transplant develops, centers requiring recommend continuous continuing immunosuppression. trimethoprim-sulfamethoxazole prophylaxis while patients are receiving any immunosuppressive drugs and also recommend careful monitoring for late CMV reactivation. In addition, many centers recommend prophylaxis against varicella zoster, using acyclovir for 1 year posttransplant. Treatment Transplantation of Specific Diseases Using Hematopoietic Cell Nonmalignant Diseases: Treatment Immunodeficiency Disorders By replacing abnormal stem cells with cells from a normal donor, hematopoietic. | Chapter 108. Hematopoietic Cell Transplantation Part 7 Pneumocystis jiroveci pneumonia once seen in 5-10 of patients can be prevented by treating patients with oral trimethoprim-sulfamethoxazole for 1 week pretransplant and resuming the treatment once patients have engrafted. The risk of infection diminishes considerably beyond 3 months after transplant unless chronic GVHD develops requiring continuous immunosuppression. Most transplant centers recommend continuing trimethoprim-sulfamethoxazole prophylaxis while patients are receiving any immunosuppressive drugs and also recommend careful monitoring for late CMV reactivation. In addition many centers recommend prophylaxis against varicella zoster using acyclovir for 1 year posttransplant. Treatment of Specific Diseases Using Hematopoietic Cell Transplantation Nonmalignant Diseases Treatment Immunodeficiency Disorders By replacing abnormal stem cells with cells from a normal donor hematopoietic cell transplantation can cure patients of a variety of immunodeficiency disorders including severe combined immunodeficiency Wiskott-Aldrich syndrome and Chédiak-Higashi syndrome. The widest experience has been with severe combined immunodeficiency disease where cure rates of 90 can be expected with HLA-identical donors and success rates of 5070 have been reported using haplotype-mismatched parents as donors Table 108-3 . Table 108-3 Estimated 5-Year Survival Rates Following Transplantation Disease Allogeneic Autologous Severe combined immunodeficiency 90 N A Aplastic anemia 90 N A Thalassemia 90 N A Acute myeloid leukemia First remission 55-60 50 Second remission 40 30 Acute lymphocytic leukemia First remission 50 40 Second remission 40 30 Chronic myeloid leukemia

• Y học thường thức
• Hematopoietic Cell Transplantation
• bệnh học và điều trị
• bài giảng bệnh học
• tài liệu học ngành y
• Harrisons Internal Medicine
• BMC Cancer
• Cumulative incidence rates
• Transplantation related mortality
• Risk factor
• Hematopoietic stem cell transplantation
• Acute leukemia
• Intestinal mucositis
• Diamine oxidase
• Circulating citrulline
• Pre HSCT factors
• Graft versus host disease
• Post traumatic stress disorder
• Hospital Anxiety and Depression Scale
• Acute lymphoblastic leukemia
• Tyrosine kinase inhibitor
• Chronic myeloid leukemia
• Kinase inhibitors
• B thalassemia major
• Fanconi’s anemia
• Immunodeficiency diseases
• Inherited metabolic disorders
• BMC Pediatrics
• Inhibin B
• Anti Müllerian hormone
• Luteinizing hormone
• Pediatric intensive care unit
• Possible predictive factors
• Pediatric critical illness score
• Peptides regulating gastrointestinal tract functions
• Gastrointestinal tract complications
• Acute graft versus
• Donor leukemia
• Whole exome sequencing
• Skin cancer
• Skin self examination
• Early detection
• Patient activation
• Veno occlusive disease
• Cytokine serum
• Interleukin 8
• Acute myeloid leukemia
• Allogeneic hematopoietic stem cell transplantation
• Wilms’ tumor gene 1
• Prognostic role
• BMC Pulmonary Medicine
• Late onset noninfectious pulmonary complications
• Pleuroparenchymal fibroelastosis
• Idiopathic pneumonia syndrome
• Childhood acute myeloid leukemia
• Allogeneic hematopoietic stem cell transplantation
• Pediatric acute myeloid leukemia
• Overall survival
• Area under the concentration time curve
• Meta analysis
• ß blocker
• Repurposed drugs
• Multiple myeloma